


Hosted by Jane Barnett jane@webbertraining.com www.webbertraining.com




Enterobacter cloacae	
Acquired IMP-4 CPE (patient 1) Acquired IMP-4 CPE (patient 2) Eclocae_ref fasta ref Comparison screening IMI-1 CPE (patient 3)	
i i i i i i i i i i i i i i i i i i i	
Klebsiella pneumoniae (no CP gene detected)	
- Reference - Acquired NCPCRE (patient 4) - Acquired NCPCRE (patient 5) - Prevalent NOPCRE (patient 6) - Prevalent NCPCRE (patient 7) - Prevalent 7)	
- 5000 - I	
n a prospective ICU screening study, none of the ICU a were clonally related. Two IMP-4 CPEs acquired in ICU were clonally related.	cquired NCPCREs


Factors Associated With Ca						and Comparative Ana NCPE)	.,		
				Univariate Analys	is	Multivariate Analysis			
Variables	CRE n = 249 (%)	CPE n = 161 (%)	NCPE n = 88 (%)	OR (95% CI)	P	OR (95% CI)	P		
Cerebrovascular disease	37 (14.9)	28 (17.4)	9 (10.2)	0.13 (0.25-1.21)	.13	0.62 (0.26-1.49)	.29		
Dementia	9 (3.6)	6 (3.7)	3 (3.4)	0.91 (0.22-3.74)	>.99				
Chronic pulmonary disease	35 (14.1)	27 (16.8)	8 (9.1)	0.50 (0.22-1.15)	.10	0.35 (0.14-0.92)	.03		
Chronic liver disease	39 (15.7)	28 (17.4)	11 (12.5)	0.68 (0.32-1.44)	.31				
Diabetes mellitus	112 (45.0)	80 (49.7)	32 (36.4)	0.58 (0.34-0.99)	.04	0.59 (0.33-1.07)	.08		
Chronic kidney disease	63 (25.3)	45 (28.0)	18 (20.5)	0.66 (0.36-1.23)	.20				
Solid tumor	68 (27.3)	43 (26.7)	25 (28.4)	1.09 (0.61-1.95)	.77				
Hernatological malignancies	25 (10.0)	10 (6.2)	15 (17.1)	3.10 (1.33-7.24)	.01	2.85 (1.10-7.41)	.03		
Antibiotic exposure in the pre	ceding 30 days								
Any antibiotics	196 (78.7)	120 (74.5)	76 (86.4)	2.16 (1.07-4.38)	.03	1.09 (0.48 - 2.48)	.83		
Carbapenems	84 (33.7)	38 (23.6)	46 (52.3)	3.55 (2.04- 6.17)	<.001	3.23 (1.67-6.25)	<.001		
Extended spectrum cephalosporins	81 (32.5)	49 (30.4)	32 (36.4)	1.31 (0.75 - 2.26)	.34				
Extended spectrum penicillins	134 (53.8)	84 (52.2)	50 (56.8)	1.21 (0.71- 2.03)	.48				
Fluoroquinolones	47 (18.9)	25 (15.5)	22 (25.0)	1.81 (0.95- 3.45)	.07	1.28 (0.61- 2.66)	.51		
Aminoglycosides	28 (11.2)	14 (8.7)	14 (15.9)	1.99 (0.90 - 4.38)	.09	1.06 (0.43- 2.65)	.89		
Dutcomes									
Length of hospitaliza- tion, median days (IQR)	38 (17- 65)	34 (17- 64)	44 (18 - 66.5)		.44				

Table 4 Multivariate analysis of risk	factors for <i>K. pneumoniae</i> acquisitio Porin-ER- <i>Kp</i> vs. controls, OR (95 % CI)	n p-value	KPC-CR-Kp vs. controls OR (95 % CI)	<i>p</i> -value
Acute renal failure	7.17 (1.33-38.6)	0.022	_	_
Endoscopy	6.12 (1.46-25.6)	0.013	6.71 (1.25-36.00)	0.026
Second-generation cephalosporins	25.7 (3.20-206.8)	0.0023	_	-
Third-generation cephalosporins	2.24 (0.80-6.31)	0.017	_	-
Carbapenems	19.10 (4.34-83.9)	< 0.001	7.74 (1.70-35.02)	0.008
Authors' discussion:	our study was that, w		lering independent (p, was associated	


Orsi, G.B. et al. Infection (2013) 41:61-67


8







Hosted by Jane Barnett jane@webbertraining.com www.webbertraining.com







Hosted by Jane Barnett jane@webbertraining.com www.webbertraining.com














































Downside of reactive infection control strate	
Reactive Infection Control Strategy for	
Control of New Delhi Metallo- β -Lactamase	
(NDM)-Producing Enterobacteriaceae	
Analyzed Using Whole-Genome	
Sequencing: Hits and Misses	
1/2 $1/2$	
Kalisvar Marimuthu, MRCP; ^{1,2a} Oon Tek Ng, MPH; ^{1a} Wei Xin Khong, PhD; ¹ Eryu Xia, BSc; ³ Yik-Ying Teo, PhD; ^{3,4,5,6,7} Rick Twee-Hee Ong, PhD; ⁴ David Chien Lye, FRACP; ^{1,2}	
Xin Khong, PhD; ¹ Eryu Xia, BSc; ³ Yik-Ying Teo, PhD; ^{3,4,5,6,7}	
Xin Khong, PhD; ¹ Eryu Xia, BSc; ³ Yik-Ying Teo, PhD; ^{3,4,5,6,7} Rick Twee-Hee Ong, PhD; ⁴ David Chien Lye, FRACP; ^{1,2} Angela Liping Chow, PhD; ⁸ Prabha Krishnan, FRCPath; ⁹ Brenda Sze Ang, MPH ¹ Genetically distinct isolates of New Delhi metallo-β-lactamase	
Xin Khong, PhD; ¹ Eryu Xia, BSc; ³ Yik-Ying Teo, PhD; ^{3,4,5,6,7} Rick Twee-Hee Ong, PhD; ⁴ David Chien Lye, FRACP; ^{1,2} Angela Liping Chow, PhD; ⁸ Prabha Krishnan, FRCPath; ⁹ Brenda Sze Ang, MPH ¹	
Xin Khong, PhD; ¹ Eryu Xia, BSc; ³ Yik-Ying Teo, PhD; ^{3,4,5,6,7} Rick Twee-Hee Ong, PhD; ⁴ David Chien Lye, FRACP; ^{1,2} Angela Liping Chow, PhD; ⁸ Prabha Krishnan, FRCPath; ⁹ Brenda Sze Ang, MPH ¹ Genetically distinct isolates of New Delhi metallo-β-lactamase (NDM)–producing <i>Enterobacteriaceae</i> were identified from the	
Xin Khong, PhD; ¹ Eryu Xia, BSc; ³ Yik-Ying Teo, PhD; ^{3,4,5,6,7} Rick Twee-Hee Ong, PhD; ⁴ David Chien Lye, FRACP; ^{1,2} Angela Liping Chow, PhD; ⁸ Prabha Krishnan, FRCPath; ⁹ Brenda Sze Ang, MPH ¹ Genetically distinct isolates of New Delhi metallo-β-lactamase (NDM)–producing <i>Enterobacteriaceae</i> were identified from the clinical cultures of 6 patients. Screening of shared-ward contacts identified 2 additional NDM-positive patients. Phylogenetic analysis proved that 1 contact was a direct transmission while the other was	





At the point of identification	1	
Dear all, 1 patient in Wardiwere tested positive for rectal swab sent on 02/05/2018 from high ris A total of 37 current inpatients have been ide The following actions are required:		
Send stool/rectal swab x 1 for CRE scre	ening. Ensure fecal matter is visible on swab.	
Order test via CCOE under Contact scre	ening - CRE (Initiated by ICN).	
 Strict Contact Precautions for all the in between patient contact and adherence 	patients undergoing screening - apron & gloves, to change e to good hand hygiene.	
Limit the patients' movement except to	ACA/HD/ICU or discharge to own home.	
 Limit group activities during this period 	L Contraction of the second	
BSU, Rehab and other institutions. For more information, please refer to the CRI	<u>t before</u> discharging/transferring patients to Nursing Home, E FAQ in the Infection Control Webpage: <u>CRE%20CPE%20FAQ%20for%20staff.pdf</u>	
Senior Staff Nurse, Infection Control Unit		
DID:		
Follow-up		
Dear all,		
The contact screening in Ward 7A has been of No current inpatient was found to be CRE pos		
Best Regards,		


Informiı	ng aff	ectec	l pati	ents]		ational Centre for fectious Diseases
New dischar	ged inpat	ient CPE	to inform	ı									
Dear Dr I A patient who was The details of the p				sed with New Dell	hi Metallo-beta-lactam	ase-1 (NDM-	1) producing Er	nterobacter cik	bacae from rec	tal swab.			
Name	NRIC	Last Ad		Ward/Bed before discharge	Inpatient Consultant I/C	Index	Date notification of CRE	Location where swab is	Culture date	Specimen	Result	Discharge to	
		Adm	Discharge	(Last adm) Ward		-	result	taken		Rectal	NDM-1	Home	
	ntly asked que	stions by the p FAQ/CRE9 ase feel free to	atient or fami	ly members and s			n the result and	document ti	he communica	ation in CDOC	5. 29		
Regards, Senior Staff Nurse, Infec	tion Control Unit												
													3

















TABLE 1 Survival times and infection from published studies ^a	ous doses retrieved o	r extrapolated	
0	Survival time	Infectious	
Organism Methicillin-resistant	7 days–>7 mo	dose 4 CFU	
Staphylococcus aureus	/ duyb / / mo	1010	
Acinetobacter	3 days–>5 mo	250 CFU	
Clostridium difficile	>5 mo	5 spores	
Vancomycin-resistant Enterococcus	5 days−>4 mo	$< 10^3 \mathrm{CFU}$	
Escherichia coli	2 h–16 mo	10 ² -10 ⁵ CFU	
Klebsiella	2 h–>30 mo	$10^2 \mathrm{CFU}$	
Norovirus	8 h–7 days	<20 virions	





		\checkmark
Criteria	UVL system	HPV system
Number of studies	13	7
Specifics	Pulsed Xenon UVL (n=8) UV-C radiation (n=4) Unspecified (n=1)	Not mentioned
Countries	US (n=13)	US (n=4) UK (n=2) Australia (n=1)
After terminal cleaning	All studies	All studies
Study years	2011-2014	2005-2012
Outcome measures		
CDI rates	11 (6 high baseline rates)	6 (2 high baseline rate)
MRSA rates	4	3
VRE rates	4	2
MDR Gram-negatives	2	0
HAI rates	1	0
SSI rates	1	0








Hosted by Jane Barnett jane@webbertraining.com www.webbertraining.com











W	ww.webbertraining.com/schedulep1.php
December 13, 2018	(FREE Teleclass) THE BEST WAYS TO GET YOUR HOSPITAL TO TALK ABOUT INFECTION CONTROL Speaker: Prof. Andreas Voss, Radboud University, The Netherlands Sponsored by Lonza (www.ionza.com)
December 14, 2018	(FREE WHO Teleclass - Europe) NEW PERSPECTIVES ON INFECTION PREVENTION AND CONTROL PROGRAM ASSESSMENTS IN THE SPIRIT OF IMPROVEMENT Speaker: Prof. Benedetta Allegranzi, World Health Association Global Infection Prevention and Control Unit Sponsored by the World Health Association
January 17, 2019	(FREE European Teleclass) THE FALLOUT OF FAKE NEWS IN INFECTION PREVENTION, AND WHY CONTEXT MATTERS Speaker: Prof. Didier Pittet, University of Geneva Hospitals, and Dr. Pierre Parneix, Hôpital Pellegrin, CHU de Bordeaux, France
January 31, 2019	BARRIERS AND FACILITATORS TO CLOSTRIDIUM DIFFICILE INFECTION PREVENTION, A NURSING PERSPECTIVE

